Tarlatamab improves long term survival in previously treated small cell lung cancer

Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer

ESMO 2026: Surgery in high-risk localised prostate cancer

Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer

ESMO 2026: Highlights and analysis

Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer

Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer

Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

ESMO 2026: Advances in NMIBC and MIBC

UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer

Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer